Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
461 to 480 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Expression of cancer stem cell markers and their prognostic significance in stage IIIA non-small cell lung cancer. | World J Stem Cells | 2025 | 41025099 | PubTator, text mining | PubMed |
| [Expression of Concern] siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells. | Exp Ther Med | 2025 | 41019485 | PubTator, text mining | PubMed |
| Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression in endometrial carcinosarcoma. | Gynecol Oncol Rep | 2025 | 41018139 | PubTator, text mining | PubMed |
| Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights. | Support Care Cancer | 2025 | 41015967 | PubTator, text mining | PubMed |
| Evaluating the Evolving Treatment Landscape of Systemic Therapies in Penile Cancer. | Cancers (Basel) | 2025 | 41008800 | PubTator, text mining | PubMed |
| Effectiveness and Safety of Sacituzumab Govitecan in Real-World Clinical Practice in Patients with Metastatic Triple-Negative and HR+/HER2-Negative Breast Cancer. | Biomedicines | 2025 | 41007623 | PubTator, text mining | PubMed |
| Immunohistochemical Evaluation of Tumor Characteristic Retention in Triple-negative Breast Cancer PDOX Models. | Anticancer Res | 2025 | 41006022 | PubTator, text mining | PubMed |
Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study. | BMC Cancer | 2025 | 40999345 | PubTator, text mining | PubMed |
| Extracellular Vesicles in Serum Carry Trop2 Protein as a Potential Molecular Indicator in Prostate Cancer. | J Extracell Biol | 2025 | 40994721 | PubTator, text mining | PubMed |
| Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives. | Cancer Treat Rev | 2025 | 40987130 | PubTator, text mining | PubMed |
| Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers. | Med Sci (Basel) | 2025 | 40981188 | PubTator, text mining | PubMed |
| Sacituzumab govitecan in Chinese patients with recurrent/metastatic cervical cancer: Results from the phase 2 EVER-132-003 basket study (NCT05119907). | Gynecol Oncol | 2025 | 40972504 | PubTator, text mining | PubMed |
| The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non-Toxic Treatment Option for Superficial Triple Negative Breast Cancer. | Cancer Med | 2025 | 40970572 | PubTator, text mining | PubMed |
| Cancer-associated fibroblasts shape the formation of budding cancer cells at the invasive front of human colorectal cancer. | Commun Biol | 2025 | 40957874 | PubTator, text mining | PubMed |
| TROP2: as a promising target in lung cancer. | Front Oncol | 2025 | 40936682 | PubTator, text mining | PubMed |
| Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors. | Cancer Immunol Res | 2025 | 40920095 | PubTator, text mining | PubMed |
| The tricky effects of TROP2 in lung cancer: from clinical practice back to fundamental investigations. | Front Oncol | 2025 | 40919144 | PubTator, text mining | PubMed |
| Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer. | Mol Diagn Ther | 2025 | 40914741 | PubTator, text mining | PubMed |
| Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis. | Cancer Res | 2025 | 40911783 | PubTator, text mining | PubMed |
| Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. | Int J Gynaecol Obstet | 2025 | 40908761 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=24